S&P 500 companies paid out $91.5 billion in dividends last quarter. Unfortunately, not all dividend stocks are created equally. Let's examine two of Big Pharma's highest-yielding stocks to determine which is the better dividend stock.
Sales of Bristol-Myers Squibb and Pfizer's Eliquis are heading higher, threatening Johnson & Johnson's market leadership among factor Xa anticoagulant drugs.
Bristol-Myers Squibb revenue fell by 4% in the second quarter, due mostly to its exit from the diabetes market.
Bristol-Myers Squibb is winning big in Japan, can they bring that success home?
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
Let's see what the numbers say about Bristol-Myers Squibb (BMY).
Spectrum, Bristol-Myers Squibb, GSK, and Theravance are the top biotech stocks to watch this morning.
Hepatitis C acquisitions like we've seen from Gilead, Bristol-Myers Squibb, and Merck can't last forever.
Yes, Pfizer should buy Bristol-Myers Squibb instead of AstraZeneca, but it won't.
Big pharma's been in a funk over the recent past with the patent cliff and the recession, but these three stocks have delivered for investors.